**Purpose:** This report provides cumulative up-to-date statistics about the emergence and landscape of novel psychoactive substances (NPS) in the United States based on data developed by the Center for Forensic Science Research and Education (CFSRE)’s NPS Discovery program — a premier open-access drug early warning system utilizing an evidence-based approach to disseminate information for real-time public health and safety action.

Since 2018, NPS Discovery has reported 154 newly discovered NPS in the United States (Figure 1). **NPS opioids** remain the largest subclass (Figure 2). In 2023, NPS Discovery reported the discovery of 17 NPS for the first time.

Since 2018, NPS Discovery has identified 240 NPS in forensic samples (Figure 3). **NPS opioids**, **stimulants**, and **cannabinoids** represent the largest subclasses observed. In 2023, 79 total NPS were detected (Figure 4).

In 2023, NPS Discovery observed more than 3,600 total NPS detections within examined sample populations (Figure 5), a portion of nearly 15,000 total NPS detections since our program launched in 2018 (Figure 6).